Клиническая фармакодинамика небиволола: новые доказательства NO-опосредованной сосудорасширяющей активности и особые гемодинамические свойства у пациентов с артериальной гипертензией

1. Ignarro LJ, Bug GM, Wood KS. Endothelium derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci 1987; 84: 9265-9. 
 Ignarro LJ. Biosynthesis and metabolism of endotheliumderived nitric oxide. Ann Rev Pharmacol Toxicol 1990; 30: 535-60.
2. Moncada S. The l-arginine nitric oxide pathway. Acta Physiol Scand 1992; 145: 201-22. 
3. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovascular Dis 1997; 39: 287-324. 
4. Rossi M, Taddei S, Fabbri A, et al. Cutaneous vasodilation to acetylcholine in patients with essential hypertension. J Cardiovasc Pharmacol 1997; 29: 406-11. 
5. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-33. 
6. Lijnder L, Kiowski W, Bu_hler FR, Lu_scher TF. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation 1990; 81: 1762-7. 
7. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-7.
8. Brush JE, Faxon DP, Salmon S, Jacobs AK, Ryan TJ. Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J Am Coll Cardiol 1992; 19: 809-15. 
9. Taddei S, Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20: 1671-4. 
10. Taddei S, Virdis A, Ghiadoni L, Salvetti A. Endothelial dysfunction in hypertension: fact or fancy? J Cardiovasc Pharmacol 1998; 32 Suppl 3: S41-7. 
11. Al Suwaidi JA, Hamasaki S, Higano ST, et al. Long term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54. 
12. Scha_chinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-906. 
13. Neunteufl T, Heher S, Katzenschlager R, et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-10. 
14. Heitzer T, Schlinzig T, Krohn K, Menertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary disease. Circulation 2001; 104: 2673-8. 
15. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6. 
16. Gao YS, Nagao T, Bond RA, Janssens WJ, Van Houtte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964-9. 
17. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmac 1994; 38: 199-204. 
18. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: Evidence for an l-arginine/NO dependent mechanism. J Pharmacol Exp Therap 1995; 374: 1067-71. 
19. Himmelmann A, Hedner T, Snoeck E, Lundgren B, Hedner J. Haemodynamic effects and pharmacokinetics of oral dand l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51: 259-64.  
20. Brett SE, Forte P, Chowienczyk, Benjamin N, Ritter JM. Comparison of the effects of nebivolol and bisoprolol on systemic vascular resistance in patients with essential hypertension. Clin Drug Invest 2002; 22: 355-9. 
21. Kubli S, Feihl F, Waeber B. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation. Clin Pharmacol Therap 2001; 69: 238-44. 
22. Dawes M, Brett SE, Chowienczyk PJ, Mant TGK, Ritter JM. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol 1999; 48: 460-3. 
23. Arosio E, De Marchi S, Prior M, Zannoni M, Lechi A. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J Hypertens 2002; 20: 1793-7. 
24. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double blind, cross-over study. Circulation 2001; 104: 511-4. 
25. Troost R, Schwedhelm E, Rojczyk S, et al. Nebivolol decreases systemic oxidative stress in healthy volunteers. Br J Clin Pharmacol 2000; 50: 377-9. 
26. Cominacini L. Nebivolol increases the availability of nitric oxide in hypertensive patients by reducing the production of superoxide. J Hypertens, submitted.
27. Kamp O, Sieswerda GT, Visser CA. Favourable effects on systolic and diastolic left ventricular function of nebivolol in comparison to atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344-8. 
28. Nodari S, Metra M, Dei Cas L. Beta blocker treatment of the patients with diastolic heart failure and arterial hypertension. A prospective, randomised comparison of the long-term effects of atenolol versus nebivolol. Eur J Heart Fail 2003; 5: 621-7. 
29. De Cree J, Geukens H, Franken P, Verhaegen H. Non invasive cardiac haemodynamics of nebivolol in men. Acta Antwerpiensia 1989; 6: 2-21.
30. De Cree J. The effect of nebivolol in patients with left ventricular diastolic dysfunction. Acta Antwepiensia 1991; 8: 10-16. 
31. Brune S, Tebbe U, Schmidt T, Kreuzern H. Haemodynamic effects of nebivolol, at rest and on exertion in patients with heart failure. Angiology 1990; 41: 696-701. 
32. Brehm BR, Wolf SC, Gorner S, Buck-Muller N, Risler T. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002; 4: 757-63. 
33. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3 month) effects of a new betablocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J. Am Coll Card 1993; 21: 1094-100.
34. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999; 43: 595-606. 
35. Grocott-Mason R, Anning P, Evans H, Lewis MJ, Shah AM. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am J Physiol 1994; 267: H1804-13. 
36. Shibata MC, Flather MD, Bohm M, et al. Study of the Effects of Nebivolol Intervention on Outocomes and Rehospitalisation in Seniors with Heart Failure (SENIORS). Rationale and design. Int J Cardiol 2002; 86: 77-85.

Реферат подготовлен по статье: A.Zanchetti. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. 
Blood Pressure 2004; 13 (Suppl 1): 18-33.